The Dermal Fillers Market size was valued at USD 6.38 billion in 2023 and is projected to grow from USD 7.3612 Billion in 2024 to USD 22.58 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.04% during the forecast period (2024 - 2032). The growing demand for facial aesthetics globally, the increasing number of aesthetic procedures performed by plastic surgeons, and cost-effective alternatives to cosmetic surgeries are driving market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
February 2024, Merz Aesthetics launched Radiesse® (+) as the first and only injectable treatment to improve moderate to severe loss of jawline contour. This product's release is accompanied by a mandatory FDA-approved training program for healthcare providers
March 2024, Medytox announced a partnership with a leading global aesthetic company to co-develop a next-generation dermal filler.
Globally, the demand for facial aesthetic treatments, products, and services is growing at a rapid pace. The growing number of medical aesthetic facilities providing aesthetic services is boosting the growth of the market. Such facilities have made these procedures more accessible and have helped in the rise of the popularity of these practices. According to the survey data published by The International Society of Aesthetic Plastic Surgery (ISAPS), aesthetic procedures have registered an increase of 19.3% in 2021 from 2020 with more than 17.5 million non-surgical and 12.8 million surgical procedures globally.
Furthermore, the cost-effective dermal filler therapy provided by some countries such as China and India is driving the market growth in the region. Furthermore, hyaluronic acid procedures are leading the segment. This is attributed to the increasing inclination of the female population towards the use of dermal fillers. Also, the growing awareness about the benefits of fillers and the need to maintain youthful structure push the sales of facial injectables.
The segmentation, based on type, includes hyaluronic acid, calcium hydroxylapatite, poly-l-lactic acid, and others. The hyaluronic acid segment held the majority share in 2022 in the revenue. This is due to the growing demand for anti-aging solutions and increasing minimally invasive aesthetic treatments. Moreover, Hyaluronic acid fillers are used primarily in non-surgical cosmetic procedures. They are mostly preferred due to their biodegradable nature, high viscosity, durability, and few hypersensitivity reactions. Additionally, they also increase hydration, improve elasticity, and protect from UV radiation.
DERMAL FILLERS MARKET SIZE, BY TYPE, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The segmentation is based on application that include facial line correction, face lift, lip enhancement, and others. The facial line correction segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is attributed to the growing consciousness about facial features and fashion, and the increasing demand for non-invasive alternative solutions for treating various types of wrinkles.
January 2020: Teoxane laboratories (Switzerland) announced an exclusive distribution agreement with Revance Therapeutics (US). This agreement provides Revance Therapeutics the right to commercialize Teoxane’s RHA line of fillers in the US, starting with its FDA-approved RHA 2, RHA 3, and RHA 4 products, as well as Teoxane’s RHA 1 dermal filler, which is currently undergoing clinical trials. This agreement provides support for the expansion of the company’s business in the US.
The segmentation is based on end user that include specialty & dermatology clinics, hospitals, and others. The specialty & dermatology clinics segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to the increasing number of dermatology clinics, and the growing number of dermatological consultations.
January 2019: Suneva Medical (US) signed two partnerships with Healeon Medical (US) and Bimini Technologies (US). With the help of this, the company aims to extend its product portfolio and brace its position in the market.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America market accounted for the largest market share in 2022. This is due to the increasing number of facial correction and improvement procedures, high per capita disposable income, and growing geriatric population in the North American region. Companies such as AbbVie Inc (US), Suneva Medical (US), GALDERMA LABORATORIES, L.P (Switzerland), and Sinclair Pharma (UK) are actively working on improving and fulfilling the demands of customers. Suneva Medical (US) company offers products to treat acne, wrinkles, and skin regeneration. The US, Canada, South Korea, Hong Kong, and Singapore are the major markets covered by Suneva Medical, Inc.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: DERMAL FILLERS MARKET SIZE, BY REGION 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe market accounts for the second-largest market share due to an increase in the number of product approvals and availability of products across the region. Furthermore, Germany market was attributed to hold the largest market share, and the UK market is expected to fastest-growing market in the European region.
The Asia-Pacific market is expected to grow at a significant share from 2023 to 2032. This is due to the rapidly growing geriatric population, rising per capita disposable income, and increasing demand for facial aesthetics products in the Asia-Pacific region. Moreover, China market is expected to hold the largest market share, and South Korea market is expected fastest-growing market in the Asia-Pacific region.
Furthermore, according to a report published by the United Nations Population Fund (UNFPA), there will be an increase in the geriatric population in the future, with an estimated 1.3 billion people over 60 in the Asia-Pacific region by 2050. Thus, as a result, the aging population boosts the market growth.
The Rest of the World is segmented into the Middle East, Africa, and Latin America. The market in the above-mentioned regions is likely to witness growth due to changing fashion trends and a focus on appearance. Moreover, limited access to treatment facilities, the market and, and limited technological advancements are also affecting the market's growth to some extent in these regions.
Dermal Fillers Key Market Players & Competitive Insights
The Market is characterized by the presence of many global, regional and local vendors. Developments in the healthcare industry and growing research and development make the market lucrative. To expand their reach and optimize their operational costs, the major players focus on obtaining regulatory authorizations from government agencies for their products and emphasize acquisitions and product launches to gain a substantial market share. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as AbbVie Inc (US), Merz Pharma (Germany), GALDERMA LABORATORIES, L.P (Switzerland), and Sinclair Pharma (UK) dominate the Market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the global industry to benefit clients and expand the sector is to manufacture locally to reduce operating costs.
AbbVie Inc (US) is a biopharmaceutical company which is discovered and delivers innovative quality medicines across the globe. AbbVie Inc. is a highly focused research-driven biopharmaceutical company. The company targets specific difficult-to-cure diseases with the help of its core research and development (R&D) expertise. The company offers dermal filler products through its subsidiary Allergan (Ireland). They constantly work to create solutions that go beyond treating the illness to have a positive impact on patient’s lives, societies, and science itself. For instance, in January 2023, Allergan, a subsidiary of AbbVie Inc (US). launched a new long-lasting product Juvederm Volux XC dermal filler. This is a long-lasting hyaluronic acid filler for severe loss of jawline definition.
Also, GALDERMA LABORATORIES, L.P (Galderma) (Switzerland)develops products in the field of aesthetics, prescription medicines, and consumer care. GALDERMA LABORATORIES, L.P. offers a wide portfolio of products used to treat different dermatological conditions. The company is present in more than 100 countries, with six manufacturing units across the world. In October 2019, the business changed its name from Nestlé Skin Health to become the biggest independent dermatology company in the world. A group of prominent institutional investors, including the EQT VIII fund, Luxinva (an entirely owned subsidiary of the Abu Dhabi Investment Authority), PSP Investments, and others, purchased it. The company works with medical professionals from all around the world to address the demands of people's skin health throughout their lifetimes. The company has a strong presence in North America, Latin America, Asia-Pacific, Europe, the Middle East, and Africa.
Key Companies in the Dermal Fillers Market include
Dermal Fillers Industry Developments
Maypharm optimized the hyaluronic acid body filler SEDY FILL in August 2023 to ensure optimal performance and customer contentment. Injectable SEDY FILL is a cutaneous filler utilized to modify the contours of the body without the need for invasive surgery. This product is distinguished by its incorporation of cross-linked hyaluronic acid produced with state-of-the-art HENM technology. The diverse range of hyaluronic acid body filler formulations enables physicians and clients to identify the most suitable option.
In May 2023, RESTYLANE EYELIGHT, a targeted therapy developed by Galderma, made its Canadian debut. Its purpose is to enhance infraorbital hollowing. HYALURonic acid (HA) injectable dermal filler RESTYLANE EYELIGHT is formulated to fill in the voids beneath the eyes, thereby eradicating the bags and diminishing the appearance of fatigue and/or aging. Hyaluronic acid is present in Galderma's product RESTYLANE EYELIGHT as a constituent of their NASHA gel technology. A local anesthetic, lidocaine, may be incorporated into the solution in order to increase the patient's tolerability during the procedure.
Dermal Fillers Type Outlook
| Attribute/Metric | Details |
| Market Size 2023 | USD 6.38 billion |
| Market Size 2024 | USD 7.361244 billion |
| Market Size 2032 | USD 22.58 billion |
| Compound Annual Growth Rate (CAGR) | 15.04% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2019 to 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, End User |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea. |
| Key Companies Profiled | AbbVie Inc (US), Dr. Korman Laboratories (Israel), Teoxane laboratories (Switzerland), SciVision Biotech Inc (Taiwan), Bridgepoint Group PLC (England), GALDERMA LABORATORIES, L.P (Switzerland), Merz Pharma (Germany), Sinclair Pharma (UK), Suneva Medical (US), and Medytox (South Korea) |
| Key Market Opportunities | · Increasing number of clinical trial studies· Rising Demand for Minimally Invasive Procedures |
| Key Market Dynamics | · Growing demand for facial aesthetics globally· Increasing number of aesthetic procedures performed by plastic surgeons· Cost-effective alternative to cosmetic surgeries |
Frequently Asked Questions (FAQ) :
The Dermal Fillers Market is anticipated to reach 22.58 billion at a CAGR of 15.04% during the forecast period of 2024-2032.
The US held over 78.61% share of the North America market for the dermal fillers market during the forecast period of 2024-2032.
The dermal fillers market is expected to grow at a 15.04% CAGR during the forecast period from 2024 to 2032.
The North American region market held the largest market share in the dermal fillers market.
The key players include AbbVie Inc (US), Dr. Korman Laboratories (Israel), Teoxane laboratories (Switzerland), SciVision Biotech Inc (Taiwan), Bridgepoint Group PLC (England), GALDERMA LABORATORIES, L.P (Switzerland), Merz Pharma (Germany), Sinclair Pharma (UK), Suneva Medical (US), and Medytox (South Korea).
The hyaluronic acid segment was estimated to lead the dermal fillers market.
The specialty & dermatology clinics segment is attributed to having the largest market share based on end user.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
